Test Drive 
, our AI Chatbot - get instant regulatory answers, free and live! Try Now
April 2026Japan has introduced a partial revision to the application process for in vitro diagnostics (IVDs), enhancing regulatory flexibility and data requirements under the Pharmaceuticals and Medical Devices Act.
Effective 01-Apr-2026 (applicable to submissions from 01-May-2026), the update expands acceptable clinical performance evidence to include not only traditional study results but also alternative data sources, such as analyses derived from real-world medical treatment data.
The revision also clarifies documentation and attachment requirements, with updates to Appendix 1 and Appendix 2 to better align application categories with required submission materials.
The guidance outlines general submission provisions, defines IVD application categories, and provides direction for assigning new generic names where none exist.
These changes aim to improve regulatory efficiency, data flexibility, and approval timelines for IVD products in Japan.
Region: Japan
Source: https://www.toku-seiyakukyo.jp/data/drug_news/2026/1_17750221207502.pdf
Reach out to us and let’s unravel your Regulatory puzzle together. Unlock regulatory solutions with our global subject matter experts and tap into a wealth of regulatory intelligence.
Speak to an Expert
